C

Calvary North Adelaide Hospital | Oncology Clinical Trials

Research site
(Unclaimed)
Location
89 Strangways Terrace, North Adelaide, South Australia, Australia
Site insights

Top conditions

Primary Myelofibrosis (1 trial)

Essential Thrombocythemia (1 trial)

Glioblastoma (1 trial)

Lymphoma (1 trial)

Prostatic Cancer (1 trial)

Top treatments

Docetaxel
Radium-223 Dichloride
AGEN2034
Rindopepimut
INCB050465
Xofigo
GM-CSF
CPI-0610
Paclitaxel
Pelabresib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

5 of 8
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

The purpose of this study is to evaluate the safety and efficacy of two parsaclisib treatment regimens in participants diagnosed with relapsed or ref...

Active, not recruiting
Lymphoma
Drug: Parsaclisib

Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and new (novel) anti-hormonal (NAH) therapy work in participan...

Enrolling
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Drug: NAH therapy
Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
Locations recently updated

A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that...

Active, not recruiting
Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis
Drug: Pelabresib
Drug: Placebo

This is a randomized, positive-controlled, open-label, international multicenter, Phase 3 clinical study to compare the efficacy and safety of pyroti...

Active, not recruiting
HER2 Exon 20 Mutation
Non-squamous NSCLC
Drug: Pyrotinib
Drug: Docetaxel

This is an open-label, multicenter, nonrandomized Phase 1 and 2 clinical trial evaluating various combinations of BGB-A425 and/or LBL-007 with tislel...

Enrolling
Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2
Drug: LBL-007
Drug: Tislelizumab

Trial sponsors

Agenus logo

Agenus (1 trial)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems